Advanced bladder cancer management: history in the making

References

• 1. The World Health Organization. 30-Bladder-fact-sheet.pdf https://gco.iarc.fr/today/data/factsheets/cancers/30-Bladder-fact-sheet.pdfGLOBOCAN2020
  Google Scholar
• 2. Bladder Cancer Prognosis and Survival Rates. NCI (2023). www.cancer.gov/types/bladder/survival
  Google Scholar
• 3. Alfred Witjes J, Max Bruins H, Carrión A et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. Eur. Urol. doi: 10.1016/j.eururo.2023.08.016. (2023) (Epub ahead of print).
  Google Scholar
• 4. Fradet Y, Bellmunt J, Vaughn DJ et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann. Oncol. 30(6), 970–976 (2019).
  Medline CASGoogle Scholar
• 5. van Dorp J, van der Heijden MS. The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition. Front Immunol 14, 1235884 (2023).
  Medline CASGoogle Scholar
• 6. Dalgleish AG. Rationale for combining immunotherapy with chemotherapy. Immunotherapy 7(3), 309–316 (2015).
  CASGoogle Scholar
• 7. Galsky MD, Arija JÁA, Bamias A et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395(10236), 1547–1557 (2020).
  Medline CASGoogle Scholar
• 8. Powles T, Csőszi T, Özgüroğlu M et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 22(7), 931–945 (2021).
  Medline CASGoogle Scholar
• 9. Powles T, van der Heijden MS, Castellano D et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 21(12), 1574–1588 (2020).
  Medline CASGoogle Scholar
• 10. van der Heijden MS, Sonpavde GP, Powles TB et al. LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase III CheckMate 901 trial. Ann. Oncol. 34, S1341 (2023).
  Google Scholar
• 11. Powles TB, Valderrama BP, Gupta S et al. LBA6 EV-302/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV + P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann. Oncol. 34, S1340 (2023).
  Google Scholar
• 12. Kawahara T, Hasizume A, Uemura K et al. Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma. Cancers (Basel) 15(17), 4227 (2023).
  Medline CASGoogle Scholar
• 13. Challita-Eid PM, Satpayev D, Yang P et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res. 76(10), 3003–3013 (2016).
  Medline CASGoogle Scholar
• 14. McGregor BA, Sonpavde G. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma. Expert Opin. Investig. Drugs 28(10), 821–826 (2019).
  Medline CASGoogle Scholar
• 15. Hoimes CJ, Flaig TW, Milowsky MI et al. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. JCO 41(1), 22–31 (2023).
  Medline CASGoogle Scholar
• 16. Lacouture ME, Patel AB, Rosenberg JE, O'Donnell PH. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. Oncologist 27(3), e223–e232 (2022).
  MedlineGoogle Scholar
• 17. Rosenberg J, Sridhar SS, Zhang J et al. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. J. Clin. Oncol. 38(10), 1041–1049 (2020).
  Medline CASGoogle Scholar
• 18. Bardia A, Tolaney SM, Punie K et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann. Oncol. 32(9), 1148–1156 (2021).
  Medline CASGoogle Scholar
• 19. Chu CE, Sjöström M, Egusa EA et al. Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clinical Cancer Research 27(18), 5123–5130 (2021).
  Medline CASGoogle Scholar